Back to Search

MASSIMO LODA, MD

MD

Clinical Pathology/Laboratory Medicine Physician

NPI: 1245306695Individual

Specialties, Licenses & Credentials

Clinical Pathology/Laboratory Medicine PhysicianPrimary

Pathology — Clinical Pathology/Laboratory Medicine

Code: 207ZP0105X

59911(MA)

Research & Publications (20)

Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma.
PMID 19040416·J Cell Mol Med·2009
8-other
Membranous expression of glucose transporter-1 protein (GLUT-1) in embryonal neoplasms of the central nervous system.
PMID 10736070·Neuropathol Appl Neurobiol·2000
7-preclinical
FOXA1 is a potential oncogene in anaplastic thyroid carcinoma.
PMID 19470727·Clin Cancer Res·2009
8-other
Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer.
PMID 19318631·J Natl Cancer Inst·2009
7-preclinical
Endothelial NOS, estrogen receptor beta, and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer.
PMID 19363294·J Clin Invest·2009
8-other
c-Jun amplification and overexpression are oncogenic in liposarcoma but not always sufficient to inhibit the adipocytic differentiation programme.
PMID 19449367·J Pathol·2009
7-preclinical
p63 promotes cell survival through fatty acid synthase.
PMID 19517019·PLoS One·2009
8-other
Gastrointestinal stromal tumors I: pathology, pathobiology, primary therapy, and surgical issues.
PMID 19664490·Semin Oncol·2009
6-review
p27Kip1 in stage III colon cancer: implications for outcome following adjuvant chemotherapy in cancer and leukemia group B protocol 89803.
PMID 19276255·Clin Cancer Res·2009
2-rct
Novel therapeutic strategies in prostate cancer: establishing a stratification system for patient selection in targeted trials.
PMID 19333896·IDrugs·2009
6-review
Mutation-specific antibodies for the detection of EGFR mutations in non-small-cell lung cancer.
PMID 19366827·Clin Cancer Res·2009
7-preclinical
Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3?
PMID 19433685·J Clin Oncol·2009
8-other
Identification of CD44v6(+)/CD24- breast carcinoma cells in primary human tumors by quantum dot-conjugated antibodies.
PMID 19488035·Lab Invest·2009
8-other
miR-29b expression is associated with disease-free survival in patients with ovarian serous carcinoma.
PMID 19509563·Int J Gynecol Cancer·2009
8-other
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.
PMID 19632176·Cell·2009
8-other
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer.
PMID 18832519·Gut·2009
8-other
Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy.
PMID 19098899·Nat Biotechnol·2009
7-preclinical
Differential requirement of mTOR in postmitotic tissues and tumorigenesis.
PMID 19176516·Sci Signal·2009
7-preclinical
Prognostic significance of altered p120 ctn expression in bladder cancer.
PMID 17922855·BJU Int·2008
8-other
Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer.
PMID 18838960·Lab Invest·2008
7-preclinical

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address
44 BINNEY STREET, DANA FARBER CANCER INSTITUTE DEPT OF PATHOLOGY
BOSTON, MA 02115

Location

Practice Location

44 BINNEY STREET, BOSTON, MA
(617) 632-4705

Quick Facts

NPI
1245306695
Entity Type
Individual
Gender
Male
Medicare
Not confirmed
Specialties
1
Locations
1
Publications
20

Are you this provider?

Claim Your Profile